NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
10631-0134-31 | 10631-0134 | Isotretinoin | Absorica | 35.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Feb 17, 2015 | In Use | |
79672-0018-01 | 79672-0018 | Oxaliplatin | Oxaliplatin | 50.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Jul 1, 2020 | In Use | |
81927-0106-01 | 81927-0106 | Thiotepa | TEPYLUTE | 10.0 mg/mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard /Ethylenimine | Intravenous | Mar 31, 2025 | In Use | |
65862-0149-05 | 65862-0149 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Oct 30, 2007 | In Use | |
68382-0775-16 | 68382-0775 | Methotrexate | Methotrexate | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | Feb 9, 2017 | In Use | |
70121-1552-05 | 70121-1552 | Methylprednisolone acetate | Methylprednisolone acetate | 80.0 mg/mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intra-articular, Intralesional, Intramuscular, Soft Tissue | Nov 1, 2021 | In Use | |
00008-0045-02 | 00008-0045 | Vinorelbine tartrate | Vinorelbine tartrate | 10.0 mg/mL | Chemotherapy | Antimitotic Agent | Vinca Alkaloid | Intravenous | Feb 13, 2008 | In Use | |
00009-0047-04 | 00009-0047 | Methylprednisolone Sodium Succinate | Solu-Medrol | 125.0 mg/2mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intramuscular, Intravenous | Apr 2, 1959 | In Use | |
00023-5906-23 | 00023-5906 | Triptorelin Pamoate | Trelstar | Hormonal Therapy | GnRH Agonist | Mar 11, 2010 | In Use | ||||
82804-0157-04 | 82804-0157 | Dexamethasone | Dexamethasone | 4.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Oct 9, 2024 | In Use | |
70771-1521-09 | 70771-1521 | Erlotinib | Erlotinib | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Apr 30, 2020 | In Use | |
00054-4582-49 | 00054-4582 | MERCAPTOPURINE | MERCAPTOPURINE | 20.0 mg/mL | Chemotherapy | Antimetabolite | Purine Analog | Oral | Feb 26, 2025 | In Use | |
00069-0454-30 | 00069-0454 | Talazoparib | Talzenna | 0.35 mg/1 | Chemotherapy | Enzyme Inhibitor | PARP | Oral | Apr 17, 2024 | In Use | |
82804-0157-20 | 82804-0157 | Dexamethasone | Dexamethasone | 4.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Apr 1, 2025 | In Use | |
68382-0363-06 | 68382-0363 | Letrozole | Letrozole | 2.5 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | Jun 3, 2011 | In Use | ||
00069-1309-04 | 00069-1309 | epoetin alfa-epbx | RETACRIT | 40000.0 [iU]/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Jun 18, 2018 | In Use | ||
62332-0730-36 | 62332-0730 | METHOTREXATE | METHOTREXATE | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | Jun 4, 2024 | In Use | |
70518-2363-02 | 70518-2363 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Feb 26, 2021 | In Use | |
63850-0128-02 | 63850-0128 | Everolimus | Everolimus | 2.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Jan 30, 2025 | In Use | |
59676-0310-02 | 59676-0310 | Erythropoietin | Procrit | 10000.0 [iU]/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Jun 1, 1989 | In Use | ||
70934-0259-42 | 70934-0259 | Prednisone | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Apr 17, 2019 | In Use | |
68071-3821-03 | 68071-3821 | Prednisone | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Apr 2, 2025 | In Use | |
72485-0222-10 | 72485-0222 | GEMCITABINE HYDROCHLORIDE | Gemcitabine | 1.0 g/26.3mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Jan 15, 2020 | In Use | |
00006-4119-01 | 00006-4119 | Human Papillomavirus 9-valent Vaccine, Recombinant | GARDASIL 9 | 40.0 ug/.5mL, 60.0 ug/.5mL, 40.0 ug/.5mL, 20.0 ug/.5mL, 20.0 ug/.5mL, 20.0 ug/.5mL, 20.0 ug/.5mL, 20.0 ug/.5mL, 30.0 ug/.5mL | Ancillary Therapy | Protective Agent | HPV Vaccine | Intramuscular | Dec 10, 2014 | In Use | |
00078-0923-61 | 00078-0923 | letrozole and ribociclib | Kisqali Femara Co-pack | 2.5 mg/1, 200.0 mg/1 | Chemotherapy, Hormonal Therapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6, Hormonal | Oral | May 4, 2017 | Aug 31, 2026 | In Use |
Found 11561 results — Export these results